Development of 2-aminooxazoline 3-azaxanthene beta-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D.
Low, J.D., Bartberger, M.D., Chen, K., Cheng, Y., Fielden, M.R., Gore, V., Hickman, D., Liu, Q., Allen Sickmier, E., Vargas, H.M., Werner, J., White, R.D., Whittington, D.A., Wood, S., Minatti, A.E.(2017) Medchemcomm 8: 1196-1206
- PubMed: 30108829 
- DOI: 10.1039/c7md00106a
- Primary Citation of Related Structures:  
5UX4, 5UYU - PubMed Abstract: 
As part of an ongoing effort at Amgen to develop a disease-modifying therapy for Alzheimer's disease, we have previously used the aminooxazoline xanthene (AOX) scaffold to generate potent and orally efficacious BACE1 inhibitors. While AOX-BACE1 inhibitors demonstrated acceptable cardiovascular safety margins, a retinal pathological finding in rat toxicological studies demanded further investigation ...